Immunomedics Appoints Robert W. Azelby to Board of Directors
February 27, 2020 16:10 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
February 27, 2020 16:00 ET
|
Immunomedics
BLA resubmitted and accepted for filing by FDA, with a June 2, 2020 PDUFA date TROPHY U-01 expanded to combine sacituzumab govitecan with Keytruda® in I/O naïve patients New investigator-initiated...
Immunomedics to Participate in Upcoming Healthcare Conferences
February 25, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27, 2020
February 20, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Appoints Dr. Loretta Itri Chief Medical Officer
February 14, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Guggenheim Healthcare Talks | Oncology Day
February 06, 2020 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer
December 26, 2019 08:00 ET
|
Immunomedics
Prescription Drug User Fee Act (PDUFA) target action date set for June 2, 2020 MORRIS PLAINS, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the...
Immunomedics Announces Closing of Public Offering of Common Stock
December 09, 2019 16:01 ET
|
Immunomedics
MORRIS PLAINS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Pricing of Public Offering of Common Stock
December 04, 2019 20:29 ET
|
Immunomedics
MORRIS PLAINS, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Proposed Public Offering of Common Stock
December 03, 2019 16:01 ET
|
Immunomedics
MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...